QuarterHawk — Equity ResearchQuarterHawk — Equity Research

Option Care Health, Inc. (OPCH)

Healthcare

No action
Fundamental
4
Sentiment
3
Technical
2

Do Nothing: no long qualifies - a dip-buy/pullback limit is countertrend (price 22.64 below SMA50 23.53 with MACD -0.25 < 0, and below a declining SMA200 with SMA50 below SMA200 without a momentum reclaim), and a breakout buy-stop above the settled 22.93 high lacks a momentum/breakout pattern (MACD negative and rolling over; price below EMA9/21 and the SMA stack); chart read is bounce-grade (score 2).

Analysis as of 2026-10-05· more than 2 trading days ago

Company overview

Option Care Health, Inc. provides home and non-hospital infusion services across the U.S., offering specialized treatments for infections, heart failure, nutritional support, and chronic conditions like ALS and Crohn's disease. The company also provides immunoglobulin infusions and supports high-risk pregnancies, pain relief, chemotherapy, and respiratory care.

Fundamental

good
Fundamental4
Solid fundamentals

Option Care Health shows strong cash generation and profitability, though growth has slowed due to reimbursement and CID headwinds.

Option Care Health is a consistently profitable, cash-generative infusion-services provider — FY2025 revenue $5.65B, net income $207.6M, ~10% TTM free-cash-flow yield, net leverage around 2.5x, an $846M undrawn revolver, and active buybacks — but revenue growth has decelerated to ~2% in 2026 on chronic-therapy attrition and reimbursement headwinds. SEC filings disclose no going-concern, covenant or liquidity concerns. Verdict: solid fundamentals with a growth-durability watch item; valuation is undemanding versus cash flow and analyst consensus ($28.43).

Sentiment

fair
Sentiment3
Mixed sentiment

Market sentiment is cautious with recent bearish revisions, despite a solid Q2 performance and insider buying.

Mixed near-term signal set: a market-rewarded Q2 beat (2026-07-29, announced) still anchors the story but is trailing and fully digested, while the freshest actionable item is a bearish sell-side revision — Argus cutting its price target to $22 (2026-10-01, announced) — and the sentiment delta is indeterminate (baseline genuinely sparse at 2 unique on-topic scored items; scoring window ~ -0.05, mildly cautious). Red-Flag Screen clean — no severe or moderate flags, no cap applied.

Technical

weak
Technical2
Weak-bearish trend

The stock is below key moving averages with no momentum, indicating a weak technical setup.

Weak-bearish, bounce-grade chart (score 2). Price 22.64 is below the full SMA/EMA stack (SMA20 23.5, SMA50 23.53, SMA200 26.5; EMA9 22.95, EMA21 23.3) with MACD -0.25/-0.09 and histogram -0.17 rolling over below zero, and RSI14 39.32 under the midline. Constructive elements - three sessions holding the 22.29-22.41 low with higher closes, Williams %R recovering from -94, volume drying up - are stabilization signals without momentum confirmation. No tradable setup type is present (no uptrend for a pullback, no deep-oversold reversal signature, no bullish MA cross, no range expansion, no momentum for a breakout), and any dip-buy limit is additionally blocked by the countertrend rule (price below SMA50 with MACD < 0; below a declining SMA200 without a reclaim).

You’re looking at 2026-10-05 — more than 2 trading days ago.

Subscribers saw this then, and see today’s score, verdict and trade plan now.

Not financial advice. For informational and educational purposes only.